<生产厂家价格>

替拉曲可

替拉曲可用途

Tiratricol是甲状腺激素类似物, 已被用来抑制垂体促甲状腺激素分泌, 降低垂体外拟甲状腺素药效。

替拉曲可名称

[ CAS 号 ]:
51-24-1

[ 中文名 ]:
替拉曲考

[ 英文名 ]:
Tiratricol

[中文别名 ]:

替拉曲可

[英文别名 ]:

triiodothyroacetic acid
Tiratricol,3,3',5-triiodothyroacetic acid
3,5,3'-triiodothyroacetic acid
3,3',5-TRIIODOTHYROACETIC ACID
Triac
Tiratricol

替拉曲可生物活性

[ 描述 ]:

Tiratricol是甲状腺激素类似物, 已被用来抑制垂体促甲状腺激素分泌, 降低垂体外拟甲状腺素药效。

[ 相关类别 ]:

信号通路 >> 其他 >> 甲状腺激素受体

研究领域 >> 内分泌

[相关活性小分子]

替拉曲可物理化学性质

[ 密度 ]:
2.5±0.1 g/cm3

[ 沸点 ]:
531.6±50.0 °C at 760 mmHg

[ 熔点 ]:
181.5ºC

[ 分子式 ]:
C₁₄H₉I₃O₄

[ 分子量 ]:
621.932

[ 闪点 ]:
275.3±30.1 °C

[ 精确质量 ]:
621.763489

[ PSA ]:
66.76000

[ LogP ]:
5.47

[ 蒸汽压 ]:
0.0±1.5 mmHg at 25°C

[ 折射率 ]:
1.767

[ 储存条件 ]:
-20°C

替拉曲可MSDS

替拉曲可安全信息

[ 符号 ]:

GHS07

[ 信号词 ]:
Warning

[ 危害声明 ]:
H302-H312-H332

[ 警示性声明 ]:
P280

[ 危害码 (欧洲) ]:
Xn: Harmful;

[ 风险声明 (欧洲) ]:
R20/21/22

[ 安全声明 (欧洲) ]:
36

[ 危险品运输编码 ]:
NONH for all modes of transport

[ WGK德国 ]:
3

[ 海关编码 ]:
2918990090

替拉曲可合成路线

替拉曲可上下游产品

替拉曲可上游产品

替拉曲可下游产品

替拉曲可海关

[ 海关编码 ]: 2918990090

[ 中文概述 ]:
2918990090. 其他含其他附加含氧基羧酸（包括酸酐、酰卤化物、过氧化物和过氧酸及该税号的衍生物）. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:30.0%

[ 申报要素 ]: 品名, 成分含量, 用途

[ Summary ]:
2918990090. other carboxylic acids with additional oxygen function and their anhydrides, halides, peroxides and peroxyacids; their halogenated, sulphonated, nitrated or nitrosated derivatives. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%

替拉曲可文献

Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.

Chem. Res. Toxicol. 23 , 171-83, (2010)

Drug-induced liver injury is one of the main causes of drug attrition. The ability to predict the liver effects of drug candidates from their chemical structures is critical to help guide experimental...

A surface on the androgen receptor that allosterically regulates coactivator binding.

Proc. Natl. Acad. Sci. U. S. A. 104 , 16074-9, (2007)

Current approaches to inhibit nuclear receptor (NR) activity target the hormone binding pocket but face limitations. We have proposed that inhibitors, which bind to nuclear receptor surfaces that medi...

Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.

J. Med. Chem. 54 , 8563-73, (2011)

The androgen receptor (AR) is the best studied drug target for the treatment of prostate cancer. While there are a number of drugs that target the AR, they all work through the same mechanism of actio...

更多文献